Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-ST-Elevation Myocardial Infarction Clear all

Conditions: Left Ventricular Dysfunction, Coronary Artery Disease
Interventions: Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more

Conditions: Non-ST Elevation Myocardial Infarction (nSTEMI)
Interventions: Admission with NSTEMI; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions: Orbital Atherectomy, Balloon; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more

Conditions: Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina, STEMI, NSTEMI - Non-ST Segment Elevation MI
Interventions: Individual Interview; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chest Pain
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,897 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
Interventions: Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 8,882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myocardial Infarction
Interventions: Percutaneous Coronary Intervention (PCI), RO4905417, placebo; Procedure · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 19 Years to 74 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 35
States / cities: Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 31 more

Conditions: Stable Angina (SA), Unstable Angina (UA), NSTEMI - Non-ST Segment Elevation MI
Interventions: Non-Fasting, Fasting; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Coronary Syndrome
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 18,624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 139
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more

Conditions: Acute Coronary Syndrome
Interventions: GW856553, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 45 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 30
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Chest Pain, Myocardial Infarction, Myocardial Ischemia, Acute Coronary Syndrome
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
Interventions: Serine proteinase-1 (Serp-1); Drug
Lead sponsor: Viron Therapeutics Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Gainesville, Florida • Grand Rapids, Michigan

Conditions: Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
Interventions: Prophylactic Impella support for a non-emergent PCI; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: Cardiac MRI, ACC/AHA Guideline adherent care; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Royal Oak, Michigan • Jackson, Mississippi • Winston-Salem, North Carolina + 1 more

Conditions: Acute Coronary Syndrome
Interventions: fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 3,235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more

Conditions: Acute Coronary Syndrome
Interventions: Clopidogrel, Prasugrel, Commercially-available Aspirin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 9,326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 165
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more

Conditions: Cardiovascular Diseases, NSTEMI, STEMI
Interventions: Bempedoic Acid / Ezetimibe Oral Tablet, Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Oakland, California

Conditions: Cardiovascular Disease, Stable Angina, Myocardial Infarction, Coronary Artery Disease
Interventions: ticagrelor; Drug
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions: Evolocumab, Routine Lipid Management; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more

Conditions: Unstable Angina, Non-ST-Elevation Myocardial Infarction
Interventions: iSTAT point of care analyzer; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myocardial Infarction
Interventions: ASC isolation and implantation; Procedure
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Coronary Atherosclerosis
Interventions: Hexadecasaccharide (SR123781A); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Acute Coronary Syndrome, STEMI, STEMI - ST Elevation Myocardial Infarction, Acute Coronary Artery Thrombosis (Diagnosis), NSTEMI - Non-ST Segment Elevation MI, Non-ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction, Non ST Segment Elevation Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction (nSTEMI), Non STEMI
Interventions: No intervention; Other
Lead sponsor: Stony Brook University; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Stony Brook, New York

Conditions: Acute Coronary Syndrome
Interventions: Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 35 Years and older
Enrollment: 3,503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 91
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more

Search by objective public record fields.

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Risk-score Based ICU Triage

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

MBCT Delivered Via Group Videoconferencing for ACS Patients With Elevated Depression Symptoms

The BEACON Registry: Best Expert Agreement for Care of Occult Myocardial Infarction (MI) Nationally

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Breaking Fasts Ahead of Cardiac Caths

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

ECG Methods for the Prompt Identification of Coronary Events

Serp-1 for the Treatment of Acute Coronary Syndrome

Restore EF Observational Study

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Diagnosis and Treatment of Acute Coronary Syndrome in the ED & the Impact of Rapid Bedside cTnl on Outcome.

Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction

Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction

EKG Criteria and Identification of Acute Coronary Occlusion

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)